The American Society of Breast SurgeonsDoes oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
References (6)
- et al.
Treatment of lymph node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials
Lancet
(2004) - et al.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
J Clin Oncol
(2006) - et al.
Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients
Cancer
(2008)
Cited by (117)
Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption
2020, Clinical Breast CancerCitation Excerpt :We did not have access to genomic recurrence risk scores. Other studies have examined this topic at length, albeit in smaller clinic-based samples rather than population-based samples, and have demonstrated an overall deescalation in chemotherapy use with receipt of the 21-gene assay, particularly in women with low-risk disease.3,4,8,21,22 A primary challenge to interpreting the impact of the 21-gene assay on chemotherapy use is the selective administration of the test, which has been reported by our group in a partly overlapping earlier cohort (2004-2009) of women with newly diagnosed, nonmetastatic, invasive breast cancer.
Short-chain fatty acids production by Bifidobacterium species in the presence of salep
2020, Electronic Journal of BiotechnologyCitation Excerpt :When fermentation substrates such as prebiotics are consumed by both animals and humans, the acidity in the colon decreases depending on the structure and dose of the prebiotics. Lower pH values result in a decrease in the growth of pathogenic bacteria and an increase in the growth of beneficial microbiota (e.g., Bifidobacteria and Lactobacilli) [8]. Thus, pH is a critical value to assess the effectiveness of candidate prebiotics in in vitro and in vivo models.
Diagnostic Pathology: Breast
2017, Diagnostic Pathology: BreastThe influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy
2016, European Journal of CancerCitation Excerpt :Although a recent systematic review found no studies to support the clinical utility of GEP (i.e. direct evidence that using GEP to direct treatment decisions improved outcomes in women with breast cancer) [14], previous qualitative research has demonstrated that patients consider GEP results a deciding factor in treatment decisions [15]. Multiple studies have examined how GEP results impact or change treatment decisions in breast cancer patients [16–22]; however, studies are lacking about the impact of GEP on decisional conflict in women from the general population, who are at risk of breast cancer and may ultimately face a decision about GEP. This is important to understand, especially in a publicly funded healthcare system where healthcare decision makers make resource allocation decisions for the population, and are increasingly incorporating public values into reimbursement decisions [23].
Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: A systematic review
2017, International Journal of Technology Assessment in Health Care